Figure 3.

Patient-derived xenograft (PDX)-clinical trial (PCT) design showing how the PDX-derived tumor is sliced, engrafted, and divided among mouse treatment groups. The technique involves precision slicing of PDX tissue and regrafting of contiguous slices across all recipient mice, noting the numerical order of each slice and its position. For each drug treatment, a minimum of 10 mice is required (five vehicle + five controls). Tumors are regrown and mice are treated with vehicle/drug and harvested for analyses.